Introduction {#s1}
============

The evolution of antifungal drug resistance is an urgent threat to human health worldwide, particularly for hospitalized and immune-compromised individuals ([@bib119]; [@bib122]; [@bib172]). Only three classes of antifungal drugs are currently available and resistance to all three classes occurred for the first time in the emerging fungal pathogen *Candida auris* ([@bib23]; [@bib59]; [@bib88]). Importantly, the mechanisms and dynamics of acquired antifungal drug resistance, in vitro or in a patient undergoing antifungal drug therapy, are not fully understood.

The most common human fungal pathogen, *Candida albicans*, causes nearly 500,000 life-threatening infections each year ([@bib22]). Disseminated bloodstream infections of *C. albicans* have a high mortality rate (15--50%) despite available antifungal therapies ([@bib121]; [@bib123]). The failure of antifungal drug therapy is likely multifactorial and is compounded by the fungistatic, not fungicidal, mechanisms of most antifungal drugs ([@bib14]; [@bib133]). Additionally, antifungal drug tolerance, the fraction of growth above an individual isolate's minimum inhibitory concentration (MIC), can cause an inability to effectively clear these fungal infections ([@bib12]). Mechanisms that cause antifungal drug tolerance are not fully understood, but likely include the induction of cell growth and division, core stress response regulators, and cell wall and cell membrane biosynthesis pathways ([@bib12]; [@bib95]; [@bib114]; [@bib135]; [@bib140]).

*C. albicans* and other fungal pathogens exhibit significant karyotype and genome plasticity ([@bib17]; [@bib26]; [@bib37]; [@bib57]; [@bib92]; [@bib149]; [@bib152]; [@bib157]; [@bib163]; [@bib184]). The genome plasticity observed in *C. albicans* isolates is somatic (asexual), based upon the absence of evidence for a meiotic cell cycle ([@bib5]; [@bib50]; [@bib75]; [@bib92]; [@bib171]), and includes whole genome duplication/reduction, aneuploidy, segmental aneuploidy, and loss of heterozygosity (LOH) ([@bib1]; [@bib44]; [@bib50]; [@bib53]; [@bib54]; [@bib58]; [@bib69]; [@bib71]; [@bib134]; [@bib138]; [@bib146]; [@bib168]). From an evolutionary prospective, the genome plasticity of *C. albicans* (and other fungal pathogens) may dramatically alter the frequency with which beneficial mutations are acquired within a population, resulting in both drug resistance and drug tolerance phenotypes.

Genome plasticity due to amplification or deletion of a chromosome segment, defined herein as copy number variation (CNV), is found across all domains of life ([@bib6]; [@bib13]; [@bib28]; [@bib40]; [@bib43]; [@bib131]; [@bib139]; [@bib179]; [@bib183]). CNVs are highly prevalent in human cancers, resulting in tumorigenesis, metastasis, and increased rates of mortality ([@bib13]; [@bib67]; [@bib70]; [@bib153]; [@bib178]). In *Saccharomyces cerevisiae*, CNVs of membrane transporters (e.g. *HXT6/7*, *CUP1, GAP1,* and *SUL1*) can provide a strong fitness benefit in nutrient limiting or high-copper environments ([@bib2]; [@bib21]; [@bib61]; [@bib62]; [@bib73]; [@bib81]; [@bib86]; [@bib118]; [@bib150]). Many CNVs occur due non-allelic homologous recombination (NAHR) between repeat sequences ([@bib28]; [@bib39]; [@bib48]; [@bib63]; [@bib66]; [@bib87]; [@bib99]; [@bib106]; [@bib125]; [@bib128]; [@bib181]). Some of these CNVs are amplified via a mechanism that relies on short repetitive sequences and aberrant base pairing during replication fork stalling ([@bib19]; [@bib18]) or DNA re-replication ([@bib48]; [@bib60]). In both *S. cerevisiae* and human cancers, extrachromosomal circular DNA (eccDNA) can also yield high copy CNVs ([@bib62]; [@bib74]; [@bib85]; [@bib101]; [@bib100]; [@bib116]; [@bib155]). Experimental evolution supports that CNVs can occur and spread rapidly within a population under selection, and competition between distinct CNV lineages (clonal interference) is frequently observed ([@bib81]; [@bib118]). Additionally, CNVs can increase the rate in which de novo mutations are acquired relative to the rest of the genome, and further alter the mutational and adaptive landscape of viral, bacterial, and eukaryotic organisms ([@bib10]; [@bib30]; [@bib43]; [@bib115]; [@bib117]; [@bib162]; [@bib177]; [@bib182]). However, in the absence of selective pressure, CNVs are generally thought to confer a fitness defect to the cell and are removed from the population ([@bib3]; [@bib166]). Therefore, the mechanism and dynamics of CNV gain and loss are critical to our understanding of adaptive evolution and pathogenesis.

Antifungal drug stress selects for aneuploidy and CNV formation in diverse human fungal pathogens, including *C. albicans, C. auris*, and *Cryptococcus neoformans *([@bib57]; [@bib76]; [@bib105]; [@bib146]; [@bib148]; [@bib157]). In *C. albicans,* a recurrent CNV that amplifies the entire left arm of Chr5 in an isochromosome (i(5L)) is sufficient to cause resistance to azole antifungal drugs ([@bib146]; [@bib147]). This resistance is due to copy number amplification of two genes on Chr5L: *TAC1,* a transcriptional activator of the multidrug transporters (*Cdr1* and *Cdr2*), and *ERG11*, the target of the azole antifungal drugs. i(5L) is frequently identified in clinical isolates and is the only CNV known to cause azole resistance in different genetic backgrounds ([@bib54]; [@bib146]; [@bib147]; [@bib169]). In addition to copy number amplification, acquisition of non-synonymous, gain-of-function mutations in *TAC1* and *ERG11* can cause resistance due to constitutive activation of drug efflux pumps and a decreased affinity to the azole drug ([@bib31]; [@bib102]). LOH of these gain-of-function alleles can increase the level of resistance even more dramatically ([@bib33]; [@bib32]; [@bib54]; [@bib140]; [@bib147]; [@bib174]).

Long repeat sequences (65 bp -- \~6.5 kb) represent a significant source of genome plasticity in *C. albicans* isolates obtained both in the presence and absence of antifungal drugs ([@bib169]). All CNV breakpoints and many LOH breakpoints occur at long repeat sequences ([@bib169]). Furthermore, CNV and LOH breakpoints frequently co-occur within the same long repeat sequences. What is not clear is whether a conserved mechanism might link CNV and LOH events during antifungal drug selection, given that both are important mechanisms of acquired antifungal drug resistance.

Through the study of *C. albicans* isolates subjected to azole antifungal drugs, we have identified a novel mechanism driving the rapid and recurrent formation of high copy CNVs. These CNVs amplify large genomic regions to more than 12 copies per genome and decrease sensitivity to multiple antifungal drugs. CNV formation appears to occur via a dicentric chromosome intermediate and successive breakage-fusion-bridge cycles that are repaired using two distinct long repeat sequences. This mechanism promotes rapid and amplifiable CNV formation during antifungal drug selection. Once the selection is relaxed, cells with the CNV can rapidly return to the progenitor copy number, leaving little evidence that the CNV ever occurred. The transient nature of these CNVs causes phenotypic and population-level heterogeneity that is often observed with clinical isolates in the presence of antifungal drug, including: heteroresistance, trailing growth, and tolerance ([@bib12]; [@bib29]; [@bib137]). Ultimately, these CNVs represent a previously uncharacterized, complex mechanism of gene amplification and chromosome plasticity that is exploited during adaptation to antifungal drug stress.

Results {#s2}
=======

Extensive copy number amplifications occur during adaptation to antifungal stress {#s2-1}
---------------------------------------------------------------------------------

To identify mechanisms driving CNV formation during adaptation to antifungal drug stress, we conducted 48 parallel in vitro evolution experiments with four drug-susceptible *C. albicans* clinical isolates, each representing a distinct genetic background (SC5314, P75016, P75063, and P78042, [Supplementary file 1](#supp1){ref-type="supplementary-material"}; [@bib71]). After 100 generations in physiological concentrations of the most commonly prescribed antifungal drug, fluconazole (FLC, 1 μg/ml) ([@bib47]), the minimum inhibitory concentration (MIC) was determined (See Materials and methods). A sub-set of the FLC-evolved isolates (14/48) that acquired at least a twofold increase in MIC~50~ relative to their progenitor were selected for whole genome sequencing (WGS). WGS analysis revealed that all (14/14) FLC-evolved isolates acquired one or more whole chromosome and/or segmental chromosome aneuploidies ([Figure 1A](#fig1){ref-type="fig"}). Half of the isolates (7/14) acquired novel CNVs (referred to herein as 'complex CNVs') that shared several key features: they had high copy numbers (up to 13 copies per genome), occurred entirely within a single chromosome arm (e.g. within Chr1R in AMS4107 and Chr4L in AMS4702), and were not associated with any centromere (*CEN*) sequence or the *C. albicans* repetitive element known as the Major Repeat Sequence (MRS, found eight times within the *C. albicans* genome) ([@bib25]; [@bib27]; [@bib82]). These complex CNVs amplified chromosome segments that ranged in length from \~164 kb to \~1.02 MB and contained 57--462 ORFs. The remaining isolates acquired either whole chromosome aneuploidies and/or segmental aneuploidies (e.g. i(5L) in AMS4106 and Chr7R in AMS4444) that had typical copy numbers (3--4 copies) and copy number breakpoints (e.g. *CEN5* in AMS4106 and *MRS7b* in AMS4444) that have been observed previously in drug-evolved isolates ([@bib146]; [@bib169]), and were not analyzed further.

![Complex CNVs are comprised of stair-step amplifications flanked by distinct long inverted repeat sequences.\
(**A**) Whole genome sequence data of FLC-evolved isolates plotted as log2 ratio and converted to chromosome copy number (y-axis, 1--12 copies) and chromosome position (x-axis, Chr1-R) using the Yeast Mapping Analysis Pipeline (YMAP). Complex CNVs amplify \>12 copies of a chromosomal region ranging from 164 kb to 1.02 Mb in length. Centromeres indicated with a red arrowhead. Chromosomal positions of all MRS sequences (black dots) and the rDNA array (blue dot) are indicated below AMS4702. The progenitor of each FLC-evolved isolate and the fold increase in FLC MIC~50~ at 48 hr between the progenitor and the FLC-evolved isolate is indicated. The symmetric stair-step CNV breakpoints for two isolates: (**B**) Chr1R of AMS4107 and (**C**) Chr4L of AMS4702. The relative genome sequence read depth is plotted according to chromosome position using R. The left and right side of each CNV (indicated with blue and orange lines along the x-axis of each chromosome) are expanded for higher resolution (left and right lower panels). In both isolates (AMS4107 and AMS4702), the CNV is flanked by two, distinct long inverted repeat sequences (blue and orange arrows) that do not share homology. The highest copy number amplification occurs between the two, distinct inverted repeats. All copy number breakpoints and long inverted repeat sequence details are found in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. All genes found within the amplified regions are found in [Supplementary file 4](#supp4){ref-type="supplementary-material"}. Repeat numbers refer to [Supplementary file 2](#supp2){ref-type="supplementary-material"} from [@bib169].](elife-58349-fig1){#fig1}

Complex CNVs are flanked by distinct long inverted repeat sequences {#s2-2}
-------------------------------------------------------------------

To identify the mechanism driving the formation of the novel complex CNVs, we determined the copy number breakpoints associated with each of the complex CNVs using a combination of read depth and allele ratio analyses. All copy number breakpoints occurred within 2 kb of one of the 1974 long repeat sequences identified previously by [@bib169] ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). However, unlike previous observations, these complex CNVs were comprised of a two-sided, stair-step amplification pattern that involved at least two distinct long inverted repeat sequences ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Accordingly, each long repeat sequence was associated with two distinct copy number changes, generating regions with different degrees of amplification, with the highest copy number always flanked by lower copy numbers ([Figure 1B and C](#fig1){ref-type="fig"}, [Supplementary file 6](#supp6){ref-type="supplementary-material"}). For example, a complex CNV on Chr1R (in AMS4107) comprised a \~218 kb region amplified to nine copies, flanked on the left and right by a region of variable length (the intra-repeat spacer length) that was amplified to six copies, that, in turn, was surrounded on both sides by a region of 2N copy number (the basal chromosome copy number). Surprisingly, the same symmetric stair-step copy number pattern (2-6-9-6-2 copies) was observed on two different chromosomes (Chr1 and Chr4) in two different genetic backgrounds (AMS4107 and AMS4702), indicating that the mechanism is neither chromosome-specific nor strain-specific ([Figure 1B and C](#fig1){ref-type="fig"}). Complex CNVs with asymmetric stair-step copy numbers also occurred due to an additional breakpoint in a third distinct long inverted repeat sequence (e.g. 2-4-6-5-3-3-2 copies in AMS4105 and 2-3-3-6-9-6-2 copies in AMS4397), that also increased the length of the CNV (see Materials and methods for determination of copy number intervals, [Supplementary file 6](#supp6){ref-type="supplementary-material"}). Of the eight complex CNVs, the highest copy number identified (2-7-13-7-2 copies) occurred in AMS4104 on Chr3R. These findings indicate that the mechanism driving the formation of these complex CNVs uses long repeat sequences, that the amplified number of copies is variable, and that both odd and even numbers of amplified copies can be detected.

Amplification of the same chromosomal region also occurred in isolates with different genetic backgrounds and from independent evolution experiments ([Figure 1A](#fig1){ref-type="fig"}). These recurrent CNVs highlight genes that are likely under selection during adaptation to FLC. For example, recurrent CNV breakpoints on Chr1R occurred at Repeats 57 and 58 in AMS4107 and AMS4105, and recurrent breakpoints on Chr3R occurred at Repeats 134 and 136 in AMS4105, AMS4397, and AMS4104 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Interestingly, while the CNV breakpoints on Chr4L were not recurrent and instead occurred at different long repeat sequences, all three of the CNVs amplified a common \~118 kb region in AMS4106, AMS4444, and AMS4702 ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Therefore, during FLC selection, complex CNV formation results in copy number amplification of recurrent chromosomal regions.

All the long inverted repeat sequences associated with the complex CNVs were contained within a single chromosome arm (intra-chromosome arm). The occurrence of intra-chromosome arm inverted repeat sequences is relatively low (77/233) within the *C. albicans* genome (excluding MRSs and ORFs which contain complex embedded tandem repeats, see [@bib169]). The repeat sequences found at these complex CNV breakpoints were among the longest (median 1513 bp) repeats, and had among the highest median shared sequence identity (96.1%) of all long repeat sequences found throughout the genome (median 516 bp, 95.1% median shared sequence identity), which is similar to repeats associated with breakpoints resulting in CNV, LOH and large chromosomal inversions in *C. albicans* isolates obtained in the presence and absence of antifungal drugs ([@bib169]).

To ask if these complex CNVs were intra-chromosomal or extra-chromosomal amplifications (e.g. eccDNA that appear in in budding yeast and cancer cells; [@bib74]; [@bib101]; [@bib100]; [@bib116]; [@bib175]), we used CHEF karyotype analyses. Separation of Chrs 4--7 identified a dramatic increase in Chr4 size in two isolates (AMS4702 and AMS4444) with Chr4L CNVs relative to their progenitors and indicates that these CNVs are intra-chromosomal, rather than extra-chromosomal, amplifications ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Because detection of CNVs on Chr1 and Chr3 was obviated by the large size of these chromosomes, restriction digest was used to characterize these intra-chromosomal amplification events (see below, e.g. Figure 3). Therefore, while we cannot completely rule out the possibility of eccDNA amplifications in some of the isolates, the increased chromosome sizes ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) support the idea that the complex CNVs are intra-chromosomal amplification events.

Surprisingly, these CNVs tended to occur within chromosomal regions that were homozygous in the progenitor isolates, making it impossible to determine which haplotype was amplified in the CNVs ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Nonetheless, for the CNVs from heterozygous progenitor sequences, the amplifications derived from only one haplotype and the allele ratio scaled with copy number (e.g. the percent majority allele was \~50--62--71--64--50 for a 2-3-4-3-2 copy CNV in AMS4106). This supports that the complex CNVs arose via a stair-step mechanism that amplified just one haplotype.

Complex CNVs increase multidrug fitness and tolerance {#s2-3}
-----------------------------------------------------

While bacteria usually exhibit a fitness tradeoff between drug resistance and fitness ([@bib7]; [@bib9]; [@bib98]), the situation is far less clear in fungal pathogens. To explore this issue comprehensively, we performed growth curve and MIC analyses across the genetically diverse isolates that had been evolved in vitro. In rich medium, the growth rate and maximum OD~600~ was similar between all FLC-evolved isolates and their progenitors ([Figure 2A--D](#fig2){ref-type="fig"}, left panels), with several notable increases in lag phase length (growth curve summary statistics provided in [Supplementary file 3](#supp3){ref-type="supplementary-material"}). In the presence of FLC (1 μg/ml), the growth rate and maximum OD~600~ were increased for all FLC-evolved isolates relative to their progenitors, and one isolate (AMS4444) grew better in FLC than in rich medium ([Figure 2A--D](#fig2){ref-type="fig"}, right panels, [Supplementary file 3](#supp3){ref-type="supplementary-material"}). While each progenitor and FLC-evolved isolate had unique growth trajectories, these observations support, in general, that the complex CNVs provided increased fitness in the presence of drug without a major cost to fitness in the absence of drug.

![Complex CNVs increase multidrug fitness and tolerance.\
(**A--D**) 36 hr growth curve analysis in the absence (YPAD, left) and presence of FLC (YPAD + 1 μg/ml FLC) for each progenitor (black) and FLC-evolved isolate with a complex CNV. Average slope and standard error of the mean for three biological replicates is indicated. (**E--F**) Heat map of isolate growth (OD~600~ at 24 and 48 hr) in two-fold increasing concentrations of the azole antifungal drugs (**E**) fluconazole (FLC) and (**F**) miconazole. The drug concentration at which 50% of growth is inhibited (MIC~50~) is denoted with a yellow line on the heat map. Each heat map represents the average of three independent MIC~50~ assays. Supra-MIC growth (SMG), a measurement of tolerance, was calculated as the average growth at 48 hr above the MIC~50~ at 24 hr divided by the growth at 48 hr in no drug (see Materials and methods, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}).\
Figure 2---source data 1.Minimum inhibitory concentration raw data.](elife-58349-fig2){#fig2}

The sub-inhibitory concentrations of FLC used in our evolution experiment and the fungistatic nature of azole antifungal drugs can select for mutants that exhibit drug tolerance: the ability to grow at drug concentrations above the MIC~50~ after 24 hr ([@bib12]; [@bib38]; [@bib135]; [@bib140]). We measured tolerance to FLC and four other azole drugs (miconazole, itraconazole, ketoconazole, and posaconazole) as supra-MIC growth (SMG), which is calculated from the average growth (OD~600~) at 48 hr for all wells above the MIC~50~ at 24 hr ([@bib12]; [@bib135]). Four of the seven isolates with complex CNVs had higher SMG levels than their progenitors in FLC, and all seven had higher SMG levels in miconazole ([Figure 2E and F](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). AMS4444 and AMS4105 had the highest SMG level in all azoles tested (0.53--0.73) and exhibited the highest growth rates and maximum OD~600~ in 1 μg/ml FLC ([Figure 2C--D](#fig2){ref-type="fig"}). Therefore, all isolates that acquired a complex CNV had increased fitness (growth rate and MIC~50~) and increased tolerance (SMG) to one or more azole antifungal drugs, and several isolates had increased tolerance to all azoles tested.

Genes involved in drug resistance and tolerance are amplified in recurrent CNVs {#s2-4}
-------------------------------------------------------------------------------

To identify genes located within the CNVs that could be driving the increased fitness in azole drugs, we first characterized genes known to cause drug resistance. We started by looking at genes with the potential to encode efflux pumps. We found that *MRR1*, the transcriptional regulator of the multidrug efflux pump Mdr1, was amplified by up to 13 copies in the three isolates with a Chr3R CNV ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Gain-of-function mutations in *MRR1* can cause constitutive upregulation and multidrug resistance ([@bib41]; [@bib103]; [@bib143]); copy number amplification alone was not previously shown to cause resistance. Additionally, multidrug transporters *CDR1* and *CDR2* map to Chr3R near *MRR1,* and these genes were amplified within the same CNV as *MRR1* in two isolates (AMS4105 and AMS4397). *MRR1* was always amplified at the highest copy number of the CNVs, while *CDR1* and *CDR2* were amplified to lower copy numbers. Finally, two other genes within the complex CNVs, *QDR2* (Chr3R) and *orf19.4889* (Chr1L), both encode predicted major facilitator superfamily (MFS) membrane transporters that may have a role in antifungal drug efflux.

Next, we searched for genes that are required for membrane and cell wall integrity, calcium and iron availability, and core stress response pathways which are likely to be important for antifungal tolerance ([@bib12]; [@bib56]; [@bib113]; [@bib114]; [@bib135]; [@bib140]; [@bib164]). The calcineurin-regulated transcription factor *CRZ1*, involved in maintenance of membrane integrity and antifungal drug tolerance ([@bib114]; [@bib140]), also maps to Chr3R and was amplified along with *MRR1, CDR1*, and *CDR2* in the same two isolates mentioned above, both of which had increased tolerance and resistance to multiple azole drugs (AMS4105 and AMS4397, [Supplementary file 4](#supp4){ref-type="supplementary-material"}). Other genes that encode other stress response proteins (*HSP70, CGR1, ERO1, TPK1, ASR1,* and *PBS2)* and proteins involved in membrane and cell wall integrity (*CDR3*, *NCP1, ECM21, MNN23*, *RHB1* and *KRE6*) were amplified in the CNVs ([Supplementary file 4](#supp4){ref-type="supplementary-material"}).

No correlation between the copy number of specific genes and the MIC~50~ or SMG observed was evident. However, since these CNVs occurred in different genetic backgrounds, that differ by \~100,000 unique SNVs, the amplification of certain alleles is likely to affect fitness differently in each isolate. For isolates from the same genetic background, the copy number of each CNV and presence of additional chromosome aneuploidies may further impact fitness. The most striking increase in FLC tolerance (SMG 0.54) was observed for an isolate (AMS4105) that acquired two different CNVs: amplification of Chr3R (containing *MRR1*, *CDR1*, *CDR2*, *QDR2*, *CRZ1,* etc.) and Chr1L (containing *ORF19.4889,* etc). A different isolate (AMS4104) from the same genetic background had the same MIC~50~ at 24 hr (as AMS4105), but no increase in tolerance (SMG = 0.13) relative to the progenitor (SMG = 0.16). AMS4104 acquired only a Chr3R CNV containing *MRR1*, but no amplification of *CDR1*, *CDR2*, *QDR2*, *CRZ1,* or the Chr1L CNV. Therefore, amplification of the *MRR1*-containing CNV correlates with an increase in the MIC~50~, while amplification of additional genes in AMS4105 on Chr3R and Chr1L (including *CDR1*, *CDR2*, and *CRZ1*) appear to have a greater impact on tolerance.

To ask if any gene functions were enriched within the complex CNVs, we performed gene ontology (GO) analysis ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). The cellular component 'nuclear microtubule' was the only GO term significantly enriched for all genes located within the complex CNVs (p\<0.008, Bonferroni correction for multiple comparisons). The 'nuclear microtubule' term included genes that encode microtubule-binding proteins involved in spindle elongation, organization, and stabilization (*ASE1*, *KIP3*, and *BIM1*), chromatin remodeling (*ISW2*), and ribosome biogenesis (*NEP1*) ([@bib34]; [@bib45]; [@bib46]; [@bib96]; [@bib110]; [@bib111]; [@bib154]; [@bib170]; [Supplementary file 4](#supp4){ref-type="supplementary-material"}). In summary, the complex CNVs amplified genes known to have a direct role in drug resistance (*MRR1*, *CDR1*, and *CDR2*) and drug tolerance (*CZR1*), as well as other roles that may be under selection during adaptation to antifungal drug stress, including maintenance of mitotic spindle function.

Expandable CNVs generated through a step-wise amplification of a dicentric chromosome {#s2-5}
-------------------------------------------------------------------------------------

The identification of recurrent CNV breakpoints in different genetic backgrounds raised the possibility that a common mechanism was driving the formation of these complex CNVs. To further address the mechanism of formation and to understand the impact of copy number on fitness, we used a set of isogenic isolates obtained from an agar plate instead of liquid cultures. These four single colony isolates (AMS3051, AMS3052, AMS3053, and AMS3054) were obtained from the same progenitor (AMS3050) after 120 hr growth on a single miconazole (20 μg/ml) agar plate ([@bib104]). Prior whole genome sequencing analysis of these colonies identified a shared CNV of Chr3L ([@bib104]). To test the hypothesis that these single colonies represented different outcomes from the same recombination event, due to the short exposure to miconazole and similarity in karyotypes, we first performed read depth analysis to characterize the CNV breakpoints. All four colonies were monosomic from the Chr3L left telomere to a shared CNV breakpoint at a long inverted repeat (Repeat 124 \[blue lines\], [Figure 3A](#fig3){ref-type="fig"}). Strikingly, the major difference between the four colonies was the maximum number of copies (3--14 copies) of the adjacent \~146 kb region on Chr3L. This region (as in [Figure 1](#fig1){ref-type="fig"}) was flanked by two distinct long inverted repeat sequences resulting in a stair-step amplification in AMS3051 and AMS3054 (Repeats 124 \[blue lines\] and Repeats 127 \[orange lines\], [Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In one isolate (AMS3052), the region of variable amplification extended beyond Repeat 127 to the centromere of Chr3 (*CEN3*). Importantly, the MIC~50~ of the miconazole-evolved colonies increased as the maximum copy number of this complex CNV increased ([Figure 3B](#fig3){ref-type="fig"}), supporting that in an isogenic background the increase in copy number directly correlates with an increase in MIC.

![Complex CNVs are rapidly expandable in the presence of antifungal drug.\
(**A**) Whole genome sequence data of progenitor isolate (AMS3050) and miconazole-evolved single colonies (AMS3053, AMS3054, AMS3052, and AMS3051) plotted as in [Figure 1A](#fig1){ref-type="fig"}. All four colonies are monosomic from the Chr3L telomere to a CNV breakpoint at Repeat 124 (blue lines). Stair-step complex CNVs (3 to 14 copies per genome) occur on Chr3L between two distinct long inverted repeat sequences: Repeat 124 (blue lines) and Repeat 127 (orange lines) (detailed in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). All four colonies are trisomic for the Chr3 centromere (*CEN3*, black circle) and all of Chr3R. (**B**) The MIC~50~ increases with the copy number of the complex CNV. Heat map of isolate growth (OD~600~ at 48 hr) in twofold increasing concentrations of miconazole. The MIC~50~ is denoted with a yellow line. Each heat map represents the average of three independent MIC~50~ assays ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). (**C**) Schematic of the homologous chromosomes in AMS3051. The full length (gray) and dicentric CNV-containing (black) homologs with the positions indicated for *CEN3* (circle), the long repeat sequences (blue and orange lines), and SacII cut sites (dashed lines). Four regions (**I--IV**) that support a breakage-fusion-bridge mechanism for the formation of complex CNVs (see main text for details). (**D**) Allele ratio plot of all heterozygous loci located within and flanking the complex CNV for AMS3050 and AMS3051. Allele ratio plots for all isolates are in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}. (**E**) SacII-digested CHEF karyotype of the progenitor and miconazole-evolved isolates (first lane of undigested AMS3050 is shown for relative size). The SacII digest isolates the region with variable copy number and *CEN3* (schematic at far right). CHEF gel stained with ethidium bromide (left panel) and analyzed by Southern blot using a DIG-labeled probe to *orf19.344,* located within the complex CNV (middle panel), and *CEN3* (right panel). Both Southern blot probes detect a novel band that increases in size as the complex CNV increases in copy number.](elife-58349-fig3){#fig3}

The isogenic isolates contained five genomic features that provide clues concerning the mechanism of complex CNV formation on Chr3L ([Figure 3C](#fig3){ref-type="fig"}): I) Monosomy (and thus LOH) extending from Repeat 124 to the telomere; II) Complex CNVs with a maximum copy number that varies between the individual colonies and amplifies unique sequences between two distinct long inverted repeats (Repeats 124 and 127); III) Trisomy of sequences extending from Repeat 127 to *CEN3*; IV) Trisomy of *CEN3* and all of Chr3R; and V) Amplification of a single haplotype in the complex CNV of Chr3L and throughout the trisomic region of Chr3R ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) (although this is not detectable in the region distal to Chr3R position 896,538, because this region is already homozygous in the progenitor). From these observations, we hypothesized that one homolog of Chr3 was intact and includes the monosomic portion of Chr3L, while the other homolog has formed a dicentric molecule that promotes breakage-fusion-bridge (BFB) cycles that result in the complex, stair-step amplifications between and within the long inverted repeats ([Figure 3C](#fig3){ref-type="fig"}).

If this hypothesis is correct, we should be able to detect dicentric chromosome intermediates by CHEF gel karyotype analysis. Because an intact dicentric Chr3 would be too large to resolve, we analyzed SacII-digested chromosomal DNA. SacII sites fall to the left of the complex CNV of Chr3L (within the monosomy) and to the right of *CEN3* yielding a fragment that should be \~480 kb in the AMS3050 progenitor ([Figure 3C and E](#fig3){ref-type="fig"}). Indeed, the progenitor and all four evolved isolates had a band of \~480 kb ([Figure 3E](#fig3){ref-type="fig"}). In addition, the four evolved isolates had an additional band of increased size (\~854 kb to \~2.16 Mb) consistent with the level of amplification in these isolates. This high-molecular-weight band hybridized to two different probes: an ORF found within the most amplified region of the Chr3L CNV (*orf19.344*) and *CEN3*. Thus, the size and content of the SacII-digested region including *CEN3* is consistent with the idea that the fragment includes a dicentric chromosome that is linked via the region containing the different-sized complex CNVs found among the AMS3050 derivatives ([Figure 3C and E](#fig3){ref-type="fig"}).

Recombination occurs between long inverted repeats leading to CNV formation {#s2-6}
---------------------------------------------------------------------------

Models of BFB in both fungal and human cells support that dicentric chromosomes form via non-allelic homologous recombination (NAHR) between inverted repeat sequences ([@bib36]; [@bib68]; [@bib112]). We used Oxford Nanopore Technology long-read sequencing to test the hypothesis that NAHR between repeat sequences was involved in the formation of the complex CNV on Chr3L in AMS3051 ([Figure 4A--C](#fig4){ref-type="fig"}) . Structural variants, indicators of recombination products not identified in the reference genome, were identified in AMS3051 using split-read alignments, read mismatching, and read depth analyses (see Materials and methods). One structural variant was detected at Repeat 124 (e.g. [Figure 4B](#fig4){ref-type="fig"}), and the other structural variant was detected at Repeat 127 (e.g. [Figure 4C](#fig4){ref-type="fig"}). Each structural variant combined unique (non-repeat) sequences, that were located up to \~100 kb apart in the reference genome, into a single long-read of only 8 kb -- 10 kb in length. Approximately 50 unique long-reads supported these structural variants and each long-read included a single copy of either Repeat 124 or Repeat 127. The individual long-reads switched between the complement and reverse complement orientation (relative to the reference) within the long repeat sequence (Repeats 124 and 127, [Figure 4B and C](#fig4){ref-type="fig"}). These long-reads represent fold-back inversions that were presumably mediated by NAHR between distant copies of the long repeat sequences. These observations, together with the intra-chromosomal CNV expansions detected by CHEF ([Figure 3E](#fig3){ref-type="fig"}), suggest that the complex CNV located on Chr3L occurs via an accordion-like expansion.

![Long-read sequencing reveals recombination products involved in the formation of complex CNVs.\
(**A**) Relative Illumina read depth for the miconazole-evolved isolate AMS3051 plotted by chromosome position (data as in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) indicating the presence of two inverted repeats (Repeat 124 (blue line) and Repeat 127 (orange line)) flanking a complex CNV on Chr3L. Repeat numbers refer to [Supplementary file 2](#supp2){ref-type="supplementary-material"} from [@bib169]. In the reference genome, Repeat 124 (**B**), consists of two inverted copies (\~99% sequence identity) that are \~3 kb in length that are \~11 kb apart and Repeat 127 (**C**) consists of two inverted copies (\~99% sequence identity) that are \~4 kb in length and located \~100 kb apart. Analysis of long-read sequences from AMS3051 identified structural variants relative to the reference genome at both Repeats 124 and 127. A single representative long-read (bottom purple line) aligned to the reference genome (top black line) is shown for Repeat 124 (**B**) and Repeat 127 (**C**). The long-read contains unique sequences that are separated by up to \~100 kb in the reference genome. Green-colored areas indicate alignment to the complement strand and gray-colored areas indicate alignment to the reverse complement strand of the reference genome. The transition between complement/reverse complement occurs within the repeat sequence. Schematics of both Repeat 124 and Repeat 127 indicate the formation of a fold-back inversion and non-allelic homologous recombination (NAHR, black and purple dashed lines) between repeat copies on sister chromatids, which could generate a dicentric chromosome. Alignment of the recombination product is inferred to produce the long-read that was detected (purple bar within the dicentric chromosomes). Each structural variant was supported by \~50 long-read sequences (see Materials and methods). All features of the CNV breakpoints are detailed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.](elife-58349-fig4){#fig4}

Loss of the CNVs and subsequent LOH in the absence of antifungal drug selection {#s2-7}
-------------------------------------------------------------------------------

Highly amplified CNVs are expected to be subject to recombination events that reduce copy number, especially if selection for the extra gene copies is relaxed. To determine the stability of the Chr3L CNV in the absence of antifungal drug, we isolated single colonies on rich medium after 72 hr. Heterogeneous populations of large and small colonies were observed for each of the four miconazole-evolved isolates ([Figure 5A and B](#fig5){ref-type="fig"}). Both a large and small colony isolated from AMS3051 were plated for single colonies on rich medium: the large colony gave rise to similarly large colonies (AMS3092), while the small colony continued to give rise to a heterogeneous population of large (AMS3093) and small (AMS3094) colonies ([Figure 5A and B](#fig5){ref-type="fig"}). WGS and read depth analysis supported that the small colony phenotype in the absence of miconazole was due to a fitness defect associated with the dicentric chromosome and/or the monosomic portion of Chr3L. In contrast, both large colonies (AMS3092 and AMS3093) had resolved the dicentric chromosome and regained the disomic portion of Chr3L ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In one case (AMS3092), the dicentric chromosome underwent a recombination event that maintained the complex CNV and heterozygosity across *CEN3* and Chr3R. In the other case (AMS3093), the dicentric chromosome underwent a recombination event at *CEN3* that returned this isolate to a euploid genotype ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) and homozygosed all of Chr3L ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). In both examples, the dicentric chromosome was never completely lost, but had recombined to resolve the dicentric.

![Complex CNVs resolve in the absence of antifungal drug by eliminating the dicentric chromosome.\
(**A**) Representative images of the progenitor (AMS3050) and the four miconazole-evolved isolates (AMS3053, AMS3054, AMS3052, and AMS3051) containing the Chr3L CNV grown on YPAD. Copy number of Chr3 (from [Figure 3](#fig3){ref-type="fig"}) shown to the right of the plate images. The notch in Chr3 is *CEN3*. Representative images below AMS3051 of single colonies derived from either a small (blue) or large (black) colony of AMS3051 on rich medium: The small colony gave rise to AMS3094 and AMS3093 and the large colony gave rise to AMS3092. Copy number of Chr3 shown below the plate images. Whole genome sequencing data are provided in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. (**B**) Colony size analysis using ImageJ (see Materials and methods), n \> 113 (up to n = 300) single colonies, three biological replicates. (**C**) Heat map of OD~600~ values taken at 48 hr in twofold increasing concentrations of miconazole. The MIC~50~ is denoted with a yellow line. Each heat map represents the average of three independent MIC~50~ assays ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). (**D**) CHEF of the parental strain and miconazole-evolved isolates. Whole genomic DNA was digested with SacII to isolate the region containing the CNV and *CEN3* (schematic to right). CHEF gel stained with ethidium bromide (left panel) and analyzed by Southern blot with DIG-labeled probes to *orf19.344* within the CNV (middle panel) and *CEN3* (right panel).](elife-58349-fig5){#fig5}

The impact of CNV loss on fitness was determined for the three single colonies derived from AMS3051 ([Figure 5C](#fig5){ref-type="fig"}). The highest MIC~50~ (4 μg/ml miconazole) was observed for both isolates with the CNV on a dicentric chromosome (AMS3051 and AMS3094). Surprisingly, the MIC~50~ decreased (2 μg/ml miconazole) for the isolate that retained the complex CNV (AMS3092) but had become euploid for all other regions on Chr3. One possibility is that, loss of the extra copy of Chr3R (which contains the multidrug resistance and tolerance genes described above: *MRR1, CDR1*, *CDR2,* and *CRZ1*) reduced the MIC~50~ of this strain. Therefore, the decrease in MIC~50~ (between AMS3051 and AMS3092) may be due to reduced copy number of these genes.

As expected, the MIC~50~ was lowest (1 μg/ml miconazole) for the isolate that returned to the euploid genotype (AMS3093). This MIC~50~ was still above the MIC~50~ of the euploid progenitor AMS3050 (0.5 μg/ml miconazole) despite the lack of de novo SNVs between the two isolates (see Materials and methods). The difference in MIC~50~ (between AMS3050 and AMS3093) may be due to the additional LOH of Chr3L that occurred during the resolution of the dicentric chromosome in AMS3093 ([Figure 5D](#fig5){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

Finally, under constant antifungal drug selection (20 μg/ml miconazole), the dicentric chromosome appeared to be highly stable by both colony morphology and karyotype analysis ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Thus, under continued antifungal drug selection the dicentric chromosome is maintained at the population and single-cell level. In contrast, removal from the selection pressure promotes the loss/resolution of the dicentric chromosome.

Discussion {#s3}
==========

This study identifies a novel mechanism for generating beneficial CNVs during adaptation to physiologically relevant concentrations of azole antifungal drugs. The formation of these complex CNVs is rapid, expandable, and reversible. Recurrent CNV breakpoints occur in clinical isolates with diverse genetic backgrounds that are exposed to azole antifungal drugs and can increase fitness across multiple azole drugs. The heterozygous diploid genome of *C. albicans* has enabled us to determine the mechanism of CNV formation from population-level and single-cell karyotype analyses. Ultimately, the expansion and contraction of these CNVs affects the rate and dynamics in which antifungal drug resistance and tolerance is acquired, and provides a plausible explanation, independent of whole chromosome aneuploidy, for the phenotypic heterogeneity frequently reported during antifungal drug susceptibility testing (e.g., tolerance or trailing growth and heteroresistance) ([@bib11]; [@bib126]; [@bib156]).

Model for complex CNV formation {#s3-1}
-------------------------------

The complex CNVs amplified recurrent chromosome regions and were associated with increased fitness in azole antifungals. Short-read and long-read whole genome sequencing revealed that all of the complex CNVs have copy number breakpoints that occur within distinct long inverted repeat sequences; in other words, the amplified regions reside between sets of different inverted repeat sequences. Based on these breakpoint sequences, we propose a model of NAHR and breakage-fusion-bridge (BFB) cycles for the formation and resolution of complex CNVs in *C. albicans* ([Figure 6](#fig6){ref-type="fig"}). For example, to generate the Chr3L complex CNV, a DNA double-strand break (DSB) occurs (the exact location of the DSB is not known) between the telomere and the telomere-proximal inverted repeat ([Figure 6A and B](#fig6){ref-type="fig"}, Repeat 124, blue arrows). This DSB generates a telomere proximal acentric fragment that is lost during future cell divisions. After DNA replication, NAHR between the long inverted repeat sequences ([Figure 6A and B](#fig6){ref-type="fig"}, Repeat 124, blue arrows) located on sister chromatids generates a dicentric chromosome and amplification of all sequence from the site of NAHR to the telomere on Chr3R ([@bib36]; [@bib79]; [@bib127]; [@bib160]). Alternatively, the dicentric chromosome could be formed via an intra-chromosomal fold-back-like mechanism between repeat copies that primes break induced replication (BIR) ([@bib106]; [@bib129]). During cytokinesis, the dicentric chromosome bridge is broken preferentially at a centromere-proximal location due to closure of the actomyosin ring ([@bib89]); the longer, monocentric chromosome fragment is followed in the model. During the next cell cycle, DNA replication generates two sister chromatids that again undergo NAHR, this time between the two copies of the centromere-proximal long inverted repeat sequence ([Figure 6A and B](#fig6){ref-type="fig"}, Repeat 127, orange arrows), which generates a second dicentric chromosome and an amplification of all sequence from the site of the second NAHR event to the telomere on Chr3R. These dicentric BFB cycles can result in heterogeneous outcomes that are beneficial in the presence or absence of antifungal drug selection including: further amplification of the repeat and unique sequences ([Figure 6C](#fig6){ref-type="fig"}); NAHR with a repeat on the other homolog, resulting in resolution of the dicentric and isolation of the CNV on a monocentric chromosome ([Figure 6D](#fig6){ref-type="fig"}, top); and recombination (likely BIR) that occurs with the other homolog at a position centromere proximal to the CNV and continues to the Chr3L telomere, resulting in loss of the complex CNV and homozygosis of Chr3L ([Figure 6D](#fig6){ref-type="fig"}, bottom). Example symmetric stair-step copy number amplifications generated by these recombination events and the presence of fold-back inversions that arise during NAHR between repeat sequences are proposed in the model ([Figure 6C and D](#fig6){ref-type="fig"}). We propose a similar model for asymmetric stair-step copy number amplifications that can form due to recombination events involving three (instead of two) distinct inverted repeat sequences ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Finally, the Chr3L CNV expansions ([Figure 3](#fig3){ref-type="fig"}, during antifungal selection) and contractions ([Figure 5](#fig5){ref-type="fig"}, when selection is relaxed) were detected after formation of a single colony and underscore the dynamic potential of these CNVs. Accordingly, we propose that a dicentric chromosome intermediate is driving the rapid generation of copy number amplifications and sub-clonal heterogeneity observed in *C. albicans* clinical isolates.

![Breakage-fusion-bridge model for the formation and resolution of complex CNVs.\
DNA double-strand breaks (DSBs), recombination, and dicentric chromosome formation can drive complex CNV formation through successive breakage-fusion-bridge (BFB) cycles. (**A**) Two distinct long-repeat sequences, Repeat 124 (blue/dark blue arrows) and Repeat 127 (orange/dark orange arrows), are located on both Chr3 homologs (black and gray). Heterozygous SNVs indicated with an X on Chr3 homolog 2. (**B**) A DSB occurs telomere proximal to the left copy of Repeat 124 on homolog 1 of Chr3, resulting in the formation of a telomere-proximal acentric DNA fragment. DNA replication generates two sister chromatids with a truncated arm. Non-allelic homologous recombination (NAHR) between Repeat 124 on sister chromatids generates a dicentric chromosome. During cytokinesis, the dicentric chromosome undergoes bridge formation and breaks near the centromere due to the closure of the actomyosin ring, generating two asymmetric chromosome fragments, each with only one centromere. The longer, monocentric chromosome fragment is followed in this model. During the next cell cycle, DNA replication generates two sister chromatids that undergo NAHR between a distinct long inverted repeat (Repeat 127, orange arrows) on sister chromatids that generates a second dicentric chromosome. Subsequent BFB cycles can result in different outcomes depending on the environmental selection: (**C**) Complex CNV expansion in which successive rounds of the BFB cycle generate CNVs with higher copy numbers, or (**D**) NAHR with a repeat on the other homolog results in the resolution of the dicentric chromosome and isolates the CNV on a monocentric chromosome (top, e.g. AMS3092). Alternatively, break induced replication (BIR) could prime near *CEN3* and continue to the Chr3L telomere, resulting in the loss of the complex CNV and homozygosis of Chr3L (bottom, e.g. AMS3093). Example stair-step copy numbers of genomic segments indicated below each schematic.](elife-58349-fig6){#fig6}

A limitation of this study is that the rate of complex CNV formation is not known, and it is also unclear whether these CNVs occur in the context of a host infection. Dicentric chromosomes have been identified in FLC-resistant clinical isolates of *C. albicans* ([@bib146]), and suggest that BFB cycles may be possible in vivo. Additionally, CNVs with breakpoints at long-repeat sequences have been identified after passage of *C. albicans* through a mouse model of oropharyngeal candidiasis (in the absence of antifungal drugs) ([@bib169]), and suggest that complex CNVs could occur in vivo. Importantly, there was very little fitness cost associated with maintaining a complex CNV on a monocentric chromosome ([Figure 2](#fig2){ref-type="fig"}), which underscores that these CNVs are well-tolerated in *C. albicans*. Ultimately, future studies using single-cell analyses (e.g. [@bib81]) are needed to determine the rate of complex CNV formation both in vitro and in vivo in the presence and absence of antifungal drugs.

Stair-step amplifications and fold-back inversions generated via BFB cycles are also observed in human cancers and developmental diseases ([@bib24]; [@bib68]; [@bib94]). For example, amplification of oncogenes (*EFGR, ERBB2, and MYC*) occurs via BFB in up to \~70% of diverse tumor types (including breast, colorectal, lung, and liver cancers) ([@bib94]; [@bib173]). While the exact molecular mechanisms of DNA repair during BFB in human cells remain under investigation ([@bib24]; [@bib91]; [@bib93]; [@bib165]), fold-back inversions causing CNVs occur more frequently (13/21 vs. 3/21) at breakpoints of microhomology (2--8 bp) than at regions of longer homology (296--330 bp, 82--95%), such as LINE, SINE, and Alu elements that are present in thousands of copies per genome ([@bib68]; [@bib132]). In comparison, the copy number breakpoints identified in *C. albicans* only occurred at long-repeat sequences (median 1513 bp) that shared high sequence identity (median 96.1%) that were predominantly present (10/12 repeats) in only two copies per genome and were always located on the same chromosome arm. Therefore, while *C. albicans* appears to have a strong preference for a BFB repair mechanism that involves homologous recombination within long-repeat sequences, the relatively low copy number of these repeat sequences in the *C. albicans* genome has enabled more precise mapping of the CNV breakpoints and fold-back inversions, whereas similar events remain challenging to resolve in the human genome.

Impact of CNVs on the mutational landscape {#s3-2}
------------------------------------------

CNVs can dramatically alter population dynamics and mutational landscapes. The rate with which CNVs occur (\~1.3×10^−6^ to \~1.5×10^−6^ per gene per cell division) is several orders of magnitude higher than the rate of SNVs (\~0.33×10^−9^ per site per cell division) in the absence of selection ([@bib90]). In the presence of strong selection, for example nutrient limitation, the rate of CNV formation can be much higher and can rapidly drive clonal interference between unique CNV-containing lineages within the population ([@bib81]; [@bib118]). Our single colony analyses support that formation of a dicentric chromosome can generate continuous cycles of genome instability and can increase population heterogeneity, which is likely to contribute to high rates of clonal interference.

We hypothesize that the complex CNVs identified here were selected due to the presence of genes that, when amplified, provide a fitness benefit in the presence of azole antifungal drugs ([@bib147]). In support of this hypothesis, *NPR2* (within the Chr3L CNV) results in increased azole resistance similar to acquisition of the CNV ([@bib104]). Other genes like *ERG11* and *TAC1* (both within the i(5L) CNV) can confer copy number dependent increases in azole resistance ([@bib147]).

In addition to the direct effect of gene amplification (i.e. more copies of the gene and its products), every cell that acquires a complex CNV also has an increased target size for the acquisition of rare, single nucleotide variants ([@bib30]; [@bib43]). CNVs therefore provide a potential for an increased likelihood of beneficial, drug-resistant point mutations during antifungal drug selection. This provides a good explanation for the utility of CNVs and aneuploidy as intermediates in the acquisition of more stable mutations (e.g. single nucleotide variants) ([@bib43]; [@bib54]; [@bib136]; [@bib162]; [@bib177]).

Importantly, many of the genes that are known to cause azole resistance contain SNVs that are recurrently found in drug-resistant isolates. For example, recurrent SNVs in *MRR1*, *ERG11, FUR1,* and *FKS1* are found in drug-resistant isolates of *C. albicans* and interestingly, are recurrent in distantly related *Candida* species as well, including *C. glabrata* and *C. auris *([@bib49]; [@bib55]; [@bib72]; [@bib103]; [@bib105]; [@bib120]). Both *MRR1* (Chr3R) and *ERG11* (Chr5L), genes with recurrent SNVs known to cause azole resistance, were amplified in CNVs in this study, supporting the idea these CNVs can amplify genes that confer increased fitness in the presence of antifungal drugs and simultaneously increase the probability that a *bona fide* drug resistance allele will occur in those same genes.

LOH is also an important mechanism of acquired antifungal drug resistance, and exposure to azole antifungal drugs can increase the frequency of LOH in *C. albicans* ([@bib16]; [@bib41]; [@bib52]; [@bib109]). Heterozygous mutations in both *MRR1* and *FKS1* also can undergo LOH in the presence of antifungal drug selection for homozygosis of the beneficial allele ([@bib41]; [@bib109]). Here, we obtained direct evidence that LOH can arise via dicentric chromosome formation and telomere-proximal chromosome loss, the same mechanism that yields complex CNVs. For example, new regions of LOH were identified during dicentric chromosome resolution (e.g. AMS4702 in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, and AMS3093 in [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). These data further support that the long repeat sequences associated with CNV and LOH breakpoints are a major source of genome plasticity in the presence and absence of antifungal drug ([@bib169]), and may underlie the variable mutation rates (hotspots) observed across an individual chromosome in other fungi as well ([@bib80]).

Finally, we found that complex CNVs frequently occurred in regions of the genome that were already homozygous in the euploid progenitors ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). We propose that such homozygous regions are the result of prior rounds of complex CNV formation and subsequent LOH in some of these isolates. Other regions of long-track homozygous sequence are frequently observed in diverse clinical isolates of *C. albicans *([@bib44]; [@bib54]; [@bib71]; [@bib134]; [@bib169]) and may provide evidence that other complex CNVs resulting in LOH are occurring in some of these isolates as well, supporting the idea that these CNVs are transient in nature.

CNVs promote antifungal drug tolerance {#s3-3}
--------------------------------------

Antifungal drug tolerance is the ability of a subpopulation of cells within a susceptible isolate to grow slowly at drug concentrations above the MIC~50~ ([@bib12]; [@bib135]). Mechanisms that contribute to the tolerance phenotype remain to be identified; however, genes involved in core stress pathways and cell wall/cell membrane biosynthesis appear to have an important role ([@bib12]; [@bib35]; [@bib135]). The complex CNVs detected here, together with what is known about drug responses in general, make it tempting to speculate on the specific genes that may be involved in the tolerance phenotype. These include genes encoding proteins involved in stress responses (*CRZ1*, *HSP70, CGR1, ERO1, TPK1, ASR1,* and *PBS2*) and cell wall/cell membrane integrity (*CDR3*, *NCP1, ECM21, MNN23*, *RHB1* and *KRE6*). We propose that amplification of these genes within transient CNVs is one major route to increase cellular fitness and generate the population heterogeneity that underlies antifungal drug tolerance.

Impact of azole antifungals on centromere function and CNV formation {#s3-4}
--------------------------------------------------------------------

Whole chromosome missegregation resulting in aneuploidy is well-documented in *C. albicans* and other fungal pathogens ([@bib51]; [@bib53]; [@bib57]; [@bib77]; [@bib108]; [@bib124]; [@bib130]; [@bib138]; [@bib146]; [@bib148]; [@bib158]; [@bib176]). Many of these aneuploidies provide a selective benefit in vitro and in vivo, and in the presence and absence of antifungal drugs. Importantly, whole chromosome aneuploidy is likely to be induced (as well as selected) by drug exposure ([@bib65]); however, the mechanisms driving chromosome mis-segregation are not well characterized.

We find that the acquisition of complex CNVs involves the formation of a dicentric chromosome intermediate. The dicentric chromosomes are maintained in the presence of drug ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}), whereas elimination of drug selection results in a \~13% increase in colonies that have lost the dicentric chromosome via subsequent recombination events that either isolate the complex CNV on a chromosome arm or revert to the euploid progenitor genotype ([Figure 5A and B](#fig5){ref-type="fig"}). Stabilization of dicentric chromosomes has been observed in humans, *Drosophila melanogaster*, Zea *mays*, and *Schizosaccharomyces pombe* due to centromere inactivation ([@bib4]; [@bib42]; [@bib64]; [@bib141]; [@bib160]; [@bib161]). Therefore, in addition to selection, we propose that the dicentric chromosome can be stabilized in the presence of azole drugs due to the depletion of Cse4/CENP-A, the centromere-specific histone H3. Importantly, Cse4/CENP-A, which is normally enriched at centromeric DNA, is depleted from the centromeres of *C. albicans* cells exposed to FLC (10 μg/ml), and contributes to an increased rate of chromosome mis-segregation ([@bib20]). Whether Cse4/CENP-A is actively removed from centromeric DNA in the presence of azole drugs is not known, but mammalian models suggest that CENP-A can be recruited away from the centromere to sites of DNA damage ([@bib180]). The presence of azole drugs may increase the likelihood that a dicentric chromosome is maintained and further increase the likelihood of recombination events that result in complex CNV formation. Therefore, determining the mechanistic link between antifungal drug treatment and centromere function is critical to understanding the genome instability that occurs during acquisition of drug resistance, including whole-chromosome aneuploidy, dicentric chromosome intermediates, and complex CNVs.

Conclusion {#s3-5}
----------

Complex CNVs are acquired rapidly during adaptation to azole antifungal drugs and cause an increase in drug resistance and tolerance. These CNVs are found across the genome, occur in diverse genetic backgrounds, and are all formed between a set of two distinct inverted repeat sequences that flank the amplified region. Evidence here provides support for a mechanism of CNV generation and resolution back to euploidy that is driven by successive BFB cycles involving a dicentric chromosome that repairs via homologous recombination between the repeat sequences. Furthermore, the cell-to-cell variability observed for clinical isolates during drug susceptibility assays may be due to the heterogeneity in the copy number of CNVs present within individual cells in a population as well as continued BFB cycles. Identification of CNVs in other pathogenic fungi, including the emerging multi-drug-resistant pathogen *C. auris,* further suggests that this mechanism of CNV formation may occur in diverse species. Together, these findings suggest a novel mechanism for transient CNV formation that increases the adaptive potential of fungal pathogens to antifungal drugs.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                               Source or reference                                                                       Identifiers                                                                         Additional\
  (species) or resource                                                                                                                                                                                                                                                                    information
  ------------------------------------------------ --------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------------------
  Strain, strain background (*Candida albicans*)   SC5314                                                    [@bib71]\                                                                                 RRID:[SCR_013437](https://scicrunch.org/resolver/SCR_013437)                        
                                                                                                             (doi:[10.1101/gr.174623.114](http://dx.doi.org/10.1101/gr.174623.114))                                                                                                        

  Strain, strain background (*C. albicans*)        P75016                                                    [@bib71] (doi:[10.1101/gr.174623.114](http://dx.doi.org/10.1101/gr.174623.114))                                                                                               

  Strain, strain background (*C. albicans*)        P75063                                                    [@bib71]\                                                                                                                                                                     
                                                                                                             (doi:[10.1101/gr.174623.114](http://dx.doi.org/10.1101/gr.174623.114))                                                                                                        

  Strain, strain background (*C. albicans)*        P78042                                                    [@bib71]\                                                                                                                                                                     
                                                                                                             (doi:[10.1101/gr.174623.114](http://dx.doi.org/10.1101/gr.174623.114))                                                                                                        

  Antibody                                         Anti-Digoxigenin-AP Fab Fragments\                        Roche                                                                                     11093274910\                                                                        (1:5000)
                                                   (Polycolonal from sheep)                                                                                                                            RRID:[AB_2734716](https://scicrunch.org/resolver/AB_2734716)                        

  Sequence-based reagent                           PCR Primers                                               This study                                                                                                                                                                    [Supplementary file 5](#supp5){ref-type="supplementary-material"}

  Commercial assay or kit                          Illumina Nextera XT Library Kit                           Illumina                                                                                  105032350                                                                           

  Commercial assay or kit                          Illumina Nextera XT Index Kit                             Illumina                                                                                  105055294                                                                           

  Commercial assay or kit                          Illumina Nextera Flex DNA Kit                             Illumina                                                                                  20018704                                                                            

  Commercial assay or kit                          Illumina Nextera DNA CN Index kit                         Illumina                                                                                  20018707                                                                            

  Commercial assay or kit                          Blue Pippin 1.5% agarose gel dye-free cassette            Sage Science                                                                              250 bp - 1.5 kb DNA size range collections, Marker R2                               Target of 900 bp

  Commercial assay or kit                          \                                                         Illumina                                                                                  \                                                                                   2 × 250 bp
                                                   Illumina MiSeq v2 Reagent Kit                                                                                                                       15033625                                                                            

  Commercial assay or kit                          1D Ligation Sequencing Kit                                Oxford Nanopore Technologies                                                              SQK-LSK108                                                                          

  Commercial assay or kit                          R9 FLO-Min106 spot-on flow cell                           Oxford Nanopore Technologies                                                              R9.4.1                                                                              

  Commercial assay or kit                          Ultra II End Repair/dA-Tailing Module                     New England Biolabs                                                                       E7546S                                                                              

  \                                                \                                                         Life Technologies                                                                         \                                                                                   
  Commercial assay or kit                          Qubit dsDNA HS kit                                                                                                                                  Q32854                                                                              

  Commercial assay or kit                          PCR DIG Probe Synthesis Kit                               Roche                                                                                     11636090910                                                                         

  Commercial assay or kit\                         Agilent 2100 Bioanalyzer High Sensitivity DNA Reagents\   Agilent Technologies\                                                                     5067--4626\                                                                         

  Commercial assay or kit\                         SacII restriction enzyme                                  New England Biolabs                                                                       R0157S                                                                              

  Chemical compound, drug                          Fluconazole (FLC)                                         Alfa Aesar\                                                                               J62015\                                                                             

  Chemical compound, drug                          Miconazole                                                Alfa Aesar                                                                                AAJ6087206                                                                          

  Chemical compound, drug                          Itraconazole                                              Alfa Aesar                                                                                AAJ6639003                                                                          

  Chemical compound, drug                          Posaconazole                                              MilliporeSigma                                                                            11-101-3331                                                                         

  Chemical compound, drug                          Ketoconazole                                              Fisher Scientific                                                                         AC455470010                                                                         

  Chemical compound, drug                          PMSF                                                      Milipore Sigma                                                                            10837091001\                                                                        

  Software, algorithm                              Trimmomatic                                               [@bib15]\                                                                                 v0.33 RRID:[SCR_011848](https://scicrunch.org/resolver/SCR_011848)\                 
                                                                                                             (doi:[10.1093/bioinformatics/btu170](https://doi.org/10.1093/bioinformatics/btu170))\                                                                                         

  Software, algorithm                              BWA                                                       [@bib84]\                                                                                 v0.7.12 RRID:[SCR_010910](https://scicrunch.org/resolver/SCR_010910)\               
                                                                                                             (doi:[10.1093/bioinformatics/btp324](http://dx.doi.org/10.1093/bioinformatics/btp324))\                                                                                       

  Software, algorithm                              Samtools                                                  [@bib83]\                                                                                 v0.1.19 RRID:[SCR_002105](https://scicrunch.org/resolver/SCR_002105)                
                                                                                                             (doi:[10.1093/bioinformatics/btp352](http://dx.doi.org/10.1093/bioinformatics/btp352))                                                                                        

  Software, algorithm                              Genome Analysis Toolkit                                   [@bib97]\                                                                                 v3.4--46 RRID:[SCR_001876](https://scicrunch.org/resolver/SCR_001876)\              
                                                                                                             (doi: [10.1101/gr.107524.110](http://dx.doi.org/10.1101/gr.107524.110))\                                                                                                      

  Software, algorithm                              Yeast Analysis Mapping Pipeline\                          [@bib1]\                                                                                  V1.0                                                                                
                                                                                                             (doi: [10.1186/s13073-014-0100-8](http://dx.doi.org/10.1186/s13073-014-0100-8))                                                                                               

  Software, algorithm                              JMP Pro                                                   <https://www.jmp.com>                                                                     V14.2.0                                                                             
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Yeast isolates and culture conditions {#s4-1}
-------------------------------------

All isolates used in this study are described in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Isolates were stored at −80°C in 20% glycerol. Isolates were cultured at 30°C in YPAD medium (yeast extract, peptone, and 2% dextrose) supplemented with 40 µg/ml adenine and 80 µg/ml uridine. For [Figure 5](#fig5){ref-type="fig"}, isolates (AMS3050, AMS3053, AMS3054, AMS3052, and AMS3051) were grown at 30°C on YPAD agar plates (yeast extract, peptone, 2% dextrose, and 2% agar) for 48 hr. One single large and one single small colony (See ImageJ colony size analysis in Materials and methods) were selected and were re-plated for single colonies on YPAD agar plates for 48 hr at 30°C. From the large colony, a single large colony (AMS3092) was selected for WGS, antifungal drug susceptibility assays (MIC~50~), colony size analysis, and CHEF analysis. From the single small colony, both a small (AMS3094) and large (AMS3093) colony were selected for WGS, antifungal drug susceptibility assays (MIC~50~), colony size analysis, and CHEF analysis.

In vitro evolution experiment {#s4-2}
-----------------------------

FLC susceptible progenitor isolates were plated for single colonies onto YPAD medium and incubated for 48 hr at 30°C. Twelve single colonies were isolated from each progenitor (SC5314, P75016, P75063, and P78042) and grown to stationary phase in 5 ml liquid YPAD to generate 48 independent lineages. A 1:1000 cell dilution was made in YPAD medium containing 1 µg/ml FLC in deep-well 96-well plates. Plates were sealed with Breathe EASIER tape (Electron Microscopy Sciences) and placed in a humidified chamber for 72 hr at 30°C. Every 72 hr, cells were resuspended and transferred into fresh medium containing 1 µg/ml FLC to a final cell dilution of 1:1000. In total, 10 transfers were conducted. After the final transfer, cells were collected for storage at −80°C, genomic DNA isolation, and MIC analysis.

Microdilution minimum inhibitory concentration (MIC) {#s4-3}
----------------------------------------------------

The MIC~50~ for each isolate was measured using a microwell broth dilution. Isolates were inoculated from frozen stocks into YPAD medium and grown for 16 hr at 30°C. Cells were diluted in fresh YPAD medium to a final OD~600~ of 0.01, and 10 µl of this dilution was inoculated into a 96-well plate containing 190 μl of a 0.5X dextrose YPAD medium with a twofold serial dilution of the antifungal drug or a no-drug control. Cells were incubated at 30°C in a humidified chamber and OD~600~ readings were taken at both 24 and 48 hr post inoculation. The MIC~50~ of each of the isolates was determined as the concentration of antifungal drug that decreased the OD~600~ by ≥50% of the no-drug control. Supra-MIC Growth (SMG) was calculated by taking the average 48 hr growth of the wells above the 24 hr MIC~50~ and dividing by the control well containing no drug ([@bib135]).

Growth curve analysis {#s4-4}
---------------------

Isolates were inoculated from frozen stocks into YPAD medium and grown for 16 hr at 30°C. Cells were diluted in fresh YPAD medium to a final OD~600~ of 0.01, and 10 µl of this dilution was inoculated into a 96-well plate containing 190 μl of a 1x dextrose YPAD medium with or without 1 μg/ml FLC. Cells were grown at 30°C in the BioTek Epoch with dual-orbital shaking (256 rpm) for 36 hr. OD~600~ readings were taken every 15 min and plotted in R (v3.5.2) using ggplot2. Each growth curve was conducted in biological triplicate in three separate experiments. Calculation of summary statistics of each growth curve was conducted using the R package Growthcurver using standard parameters ([Supplementary file 3](#supp3){ref-type="supplementary-material"}; [@bib159]).

Contour-clamped homogenous electric field (CHEF) electrophoresis {#s4-5}
----------------------------------------------------------------

Sample plugs were prepared as previously described ([@bib145]). Briefly, cells were suspended in 300 µL 1.5% low-melt agarose (Bio-Rad) and digested with 1.2 mg Zymolyase (US Biological) at 37°C for 16 hr. Plugs were washed twice in 50 mM EDTA and treated with 0.2 mg/ml proteinase K (Alpha Azar) at 50°C for 48 hr. For samples digested with SacII, plugs were washed twice with 1x TE and incubated in 1 mM PMSF (Milipore Sigma) at room temperature for 30 min, washed twice with 1X TE and suspended in 1X CutSmart Buffer (New England Biolabs), and digested with 30 units of SacII (New England Biolabs) at 37°C for 24 hr. Chromosomes were separated in a 1% Megabase agarose gel (BioRad) in 0.5X TBE using the CHEF DRIII Pulsed Field Electrophoresis System. For whole chromosome separation, run conditions as follows: 60 s to 120 s switch, 6 V/cm, 120° angle for 36 hr followed by 120 s to 300 s switch, 4.5 V/cm, 120° angle for 12 hr. SacII digested chromosomes were separated as follows: 7 s to 100 s switch, 4.5 V/cm, 120° angle for 21 hr followed by 80 s to 400 s switch, 3.5 V/cm, 120° angle for 21 hr. CHEF gels were stained with ethidium bromide and imaged with the GelDock XR Imaging system (BioRad).

Southern blot hybridization {#s4-6}
---------------------------

Chromosomes from CHEF gels were transferred to a BrightStar Plus nylon membrane (Invitrogen). Hybridization and detection of the DNA was conducted as previously described ([@bib145]; [@bib147]; [@bib148]; [@bib169]). Probes were generated through PCR incorporation of DIG-11-dUTP into target sequences following the manufacturer's instructions (Roche). Primers used in this study are located in [Supplementary file 5](#supp5){ref-type="supplementary-material"}.

Gene Ontology (GO) analysis {#s4-7}
---------------------------

GO analysis was conducted for all terms (process, function, and component) using the GO Term Finder from the Candida Genome Database (CGD accessed 03/03/2020, <http://www.candidagenome.org/cgi-bin/GO/goTermFinder>). All genes located within the complex CNVs were included in the analysis. Genes located in other aneuploid chromosomes (AMS4104 - Chr7; AMS4106 - Chr3, i(5L); AMS4444 - Chr3, Chr4R, Chr7R) were not included in the GO analysis. Terms were considered significantly enriched if p\<0.05. GO enrichment was determined for all genes included in the complex CNVs, as well as for each CNV individually ([Supplementary file 4](#supp4){ref-type="supplementary-material"}).

ImageJ colony size analysis {#s4-8}
---------------------------

All agar plates were imaged using the GelDock XR Imaging system (Bio-rad) using the same zoom and focal length. Images were exported as .png files, converted to eight-bit, and analyzed with Fiji (v2.0.0-rc-30/1.49 s) ([@bib142]). An automatic threshold was set using the RenyiEntropy algorithm and the area of each particle was measured ([@bib151]). Colonies were considered small if their total area was less than two standard deviations below the mean colony size of the progenitor isolate, AMS3050 in the absence of miconazole. Colony size of each isolate, in the absence or presence of 20 μg/ml miconazole, was obtained from three individual agar plates (n \> 113).

Illumina whole genome sequencing {#s4-9}
--------------------------------

Genomic DNA was isolated using a phenol-chloroform extraction as described previously ([@bib146]). Libraries were prepared using either the Illumina Nextera XT DNA Library Preparation Kit or the Nextera DNA Flex Library Preparation Kit. Adaptor sequences and low-quality reads were trimmed using Trimmomatic (v0.33 LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:36 TOPHRED33) ([@bib15]). Trimmed reads were mapped to the *C. albicans* reference genome (A21-s02-m09-r08) from the *Candida* Genome Database (<http://www.candidagenome.org/download/sequence/C_albicans_SC5314/Assembly21/archive/C_albicans_SC5314_version_A21-s02-m09-r08_chromosomes.fasta.gz>). Reads were mapped using BWA-MEM (v0.7.12) with default parameters ([@bib84]). PCR duplicated reads were removed using Samtools (v0.1.19) ([@bib83]), and realigned around predicted indels using the Genome Analysis Toolkit (RealignerTargetCreator and IndelRealigner, v3.4--46) ([@bib97]). All Illumina data have been deposited in the National Center for Biotechnology Information Sequence Read Archive database under PRJNA613282.

Visualization of aneuploid chromosomes {#s4-10}
--------------------------------------

Aneuploid chromosomes were visualized using the Yeast Analysis Mapping Pipeline (YMAP v1.0) ([@bib1]). Fastq files were uploaded to YMAP and read depth was determined and plotted as a function of chromosome position. Read depth was corrected for both GC-content and chromosome-end bias.

Read depth analysis plots {#s4-11}
-------------------------

For each isolate, read depth for each position within the genome was calculated using samtools depth (`--aa`) (v0.1.19) ([@bib83]). A sliding window of 500 bp was used to calculate the average read depth over a given genome segment and normalized to the average read depth of the nuclear genome. Read depth analysis was visualized in R (v3.5.2) using ggplot2. Compiled read depth analysis found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}.

CNV breakpoint detection {#s4-12}
------------------------

Chromosomes containing CNVs were detected using the Yeast Mapping Analysis Pipeline (YMAP v1.0 \[[@bib1]\]). Fastq files were uploaded and mapped to the SC5314 reference genome (A21-s02-m08-r09) with correction for GC-content and chromosome end bias. Estimated copy number breakpoints were detected using Aneufinder (v1.10.2), with a bin width of 42.5 kb ([@bib8]). The bins containing estimated breakpoints were identified for further analysis. Estimated breakpoints located at the MRSs were not analyzed due to the repetitive nature and poor mapping of these genomic regions. To further refine copy number breaks, fastq files were aligned to the SC5314 reference genome (see above) and read depth was determined for each nucleotide in the genome (samtools depth `--aa`, v0.1.19). Read depth was normalized to the mean read depth of the nuclear genome using R (v3.5.2). The 42.5 kb windows containing estimated copy number breakpoints as determined by Aneufinder were further subdivided into 500 bp windows. The mean normalized read depth was determined for these 500 bp windows and a rolling mean of every two consecutive 500 bp windows was determined using R. Copy number breakpoints were identified if 75% of four consecutive 500 bp windows had a mean normalized read depth that deviated from the mean nuclear genome read depth by more than 25% ([@bib54]). Boundaries were further confirmed by visual inspection in Integrative Genomics Viewer (IGV v2.3.92) ([@bib167]). CNV breakpoint positions were compared to the list of long repeat sequences found across the *C. albicans* genome described in [Supplementary file 2](#supp2){ref-type="supplementary-material"} of [@bib169] and breakpoints were assigned a repeat name if they fell within 2 kb of a long repeat sequence ([@bib169]).

Copy number detection of complex CNVs {#s4-13}
-------------------------------------

For each isolate, read depth for each position within the genome was calculated using samtools depth (`--aa`) (v0.1.19) ([@bib83]). A sliding window of 500 bp was used to calculate the average read depth over a given genome segment and normalized to the average read depth of the nuclear genome. Each segment of the chromosome containing a complex CNV (high copy number central region and all lower copy number flanking sequences, including the disomic regions) was then assigned a copy number using the average normalized read depth of the 500 bp windows located within that given CNV segment multiplied by two for the diploid genome. If a 500 bp window contained a known repeat sequence (including those associated with copy number breakpoints) that window was excluded from analysis due to read mapping errors that occur in repetitive sequences. Likewise, telomere proximal regions were excluded from analysis. Telomere proximal regions were determined as the start or end of each chromosome to the first confirmed, non-repetitive genome feature as previously described ([@bib44]; [@bib71]; [@bib169]). The read depth for each segment was then normalized to the average read depth of the disomic segments of the chromosome to normalize for chromosome copy number, and rounded to the nearest integer for the final copy number. The copy number data, as well as read depth summary statistics for each chromosome segment are found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. Data were analyzed and summary statistics were generated using JMP Pro (v14.2.0).

Allele ratio analysis {#s4-14}
---------------------

Heterozygous positions were determined using the Genomics Analysis Toolkit's HaplotypeCaller (v3.7--0-gcfed67) with a standard minimum confidence threshold of phred30 (-stand_call_conf 30) ([@bib97]). Variants were analyzed if the read depth was \>2 and the variant was sequenced on both the forward and reverse strand. Additional filtering of SNVs included the removal of ancestral homozygous positions, homozygous SNVs that were maintained within the progenitor and all evolved isolates and not the reference SC5314. SNVs contained within long-repeat sequences were also removed due to the mapping errors with short read sequencing in repetitive regions.

Variant calling {#s4-15}
---------------

De novo variant detection was conducted using aligned, sorted BAM files that were converted to mpileup files using Samtools (samtools mpileup) ([@bib83]). VCFs were generated using Varscan (V2.3) ([@bib78]). Called variants were filtered under the following conditions: 1) All SNVs shared by all progeny are removed and are assumed to be parentally derived, 2) a read depth of \<5, and 3) a percent alternative allele of \<0.2.

Oxford Nanopore Technology MinION sequencing and de novo alignment {#s4-16}
------------------------------------------------------------------

Two identical libraries of AMS3051 were constructed using the 1D Ligation Sequencing Kit (SQK-LSK108) from Oxford Nanopore following manufacturers protocol with slight modification. Briefly, end repair and dA-tailing was performed following New England Biolabs protocol for the Ultra II End-prep reaction (NEB E7546S) with a 30 min incubation at 20°C followed by a 30 min incubation at 65°C. The DNA was then purified using 1.8x Ampure beads (Agencourt). Adapter ligation was allowed to incubate at room temperature for 30 min followed by a 0.6x Ampure (Agencourt) bead cleanup. Data was generated using the R9 FLO-MIN106 spot-on flow cell. Calibration of the flow cell indicated 1171 active pores across the four mux groups. The library was loaded following manufacturers recommendation and sequencing was allowed to proceed for 24 hr before loading with the second library. Sequencing continued for another 24 hr before the sequencing run was terminated. A total of 910753 reads were obtained with a mean read length of 2210 bp (minimum 5 bp and maximum 352979 bp). Average theoretical coverage was 129.9x assuming a haploid genome size of 15.5 Mb.

Visualization of Oxford Nanopore Technology MinION sequencing data {#s4-17}
------------------------------------------------------------------

Oxford Nanopore minion Fastq files from AMS3051 were aligned to the SC5314 reference genome (A21-s02-m09-r08) using NGMLR (-x ont, v0.2.7) ([@bib144]). The resulting SAM file was converted to a BAM file using samtools view (-S --b) and was sorted and indexed using samtools sort and samtools index, respectively (v0.1.19) ([@bib83]). Structural variant detection was conducted using Sniffles (v1.0.11) ([@bib144]) and the average binned (10 kb) read coverage was determined using Copycat (<https://github.com/MariaNattestad/copycat>). Structural variants were identified using SplitThreader (<http://splitthreader.com>). Individual discordant reads were identified and visualized using Ribbon with a minimum alignment length of 1 kb ([@bib107]).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

We appreciate your efforts to address all the comments raised by the three reviewers, and we like how your work further unravels how medium-sized repeats in the *C. albicans* genome contribute to its capacity to quickly and reversibly adapt to certain stresses by stimulating amplification as well as loss of genomic regions.

**Decision letter after peer review:**

Thank you for submitting your article \"Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Patricia Wittkopp as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: David Gresham (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

We appreciate how this new study expands on your earlier work by showing how repeats are instrumental in facilitating transient amplifications of certain genomic loci that can help *C. albicans* become tolerant to drugs.

As you can see below, all three reviewers agree that your paper is interesting and well written, and we do not see a necessity for additional experiments. That said, all reviewers did mention that some points merit some additional clarification or discussion. Whereas some comments overlap, other points were only raised by one reviewer, likely reflecting the different expertise of the reviewers. However, we agree that all points that are raised are in fact valid and may help you to improve the paper and make it (even) more accessible and interesting to a broad readership. Hence, in this case, it seemed useful to copy all three separate reviews below instead of merging them all into one common file.

Reviewer \#1:

In a previous study (*eLife* https://doi.org/10.7554/*eLife*.45954.001), this team showed how long repeat sequences scattered throughout the *C. albicans* genome fuel recombination events that lead to CNV and LOH. In this follow-up study, the authors show how subjecting *C. albicans* to antifungal drugs (fluconazole) leads to the selection of CNV in the form of large segmental duplications. The amplified regions ranged from 100 to 1000kb, often contain genes that have previously been associated with drug resistance, and some were amplified up to 12 times. Interestingly, the breakpoints always occurred within 2kb of long inverted repeat sequences, again suggesting that these repeats drive the recombination events. Moreover, removal of the antifungal drugs led to loss of the duplicated regions and return to the initial geno- and phenotype, suggesting that the extra copies impose a negative fitness effect the repeats also facilitate the loss of repeats.

Overall, whereas the idea of 1) CNVs as an adaptive process and 2) repeats as facilitators of genome instability are not new, this study is a useful follow up to the previously published work because it provides more mechanistic insight into the recombination events that allow adaptation to antifungals through swift amplification of certain chromosomal regions. Moreover, the study also shows that the amplification confers a fitness defect in environments without drugs, and how the amplification is quickly lost when the selective pressure disappears. Together, this reveals how medium-sized repeats in the *C. albicans* genome contribute to its capacity to quickly (and reversibly) adapt to certain stresses by stimulating amplification as well as loss of genomic regions.

Reviewer \#2:

In this paper, Todd and Selmecki report copy number variants (CNVs) that arise in response to selection for antifungal resistance. The authors performed 48 evolution experiments in four different genetic backgrounds. Seven isolates that showed increased drug resistance were analyzed using DNA sequencing and CHEF gels. They identify high copy number amplifications of chromosomal segments in resistant clones that do not result from previously reported mechanisms (i.e. centromere amplifications, aneuploidy and use of major repeat sequences (MRS)). The novel CNVs have breakpoints that are near long repeat sequences and are characterized by an intrachromosomal symmetric stair-step pattern of copy number increase. The amplified regions contain several genes and the authors identify likely targets of selection including MRR1, which regulates drug efflux pump expression. Detailed analysis of one set of CNVs provides evidence for the formation of a dicentric region and repeat expansion through a breakage-fusion-bridge mechanism. They then show that when the selection is removed, CNVs rapidly revert.

This is an interesting study. Understanding mechanisms of antifungal resistance is of clear significance and this paper adds to our understanding of the diversity of mechanisms that can be used to generate CNVs underlying drug resistance in *C. albicans*. Although I do not think that the finding is sufficiently novel to warrant publication as a primary research paper in *eLife*, the report extends the initial publication by the authors on repeat sequences that mediate CNV formation in the *C. albicans* genome and therefore is consistent with the aims of the Research Advance format at *eLife*.

1\) It is unclear to me the difference between a major repeat sequence (MJR) and a repeat sequence. The authors state that these breakpoints do not occur near MJR, but do occur \"within 2 kb of a long repeat sequence\". What is the difference?

2\) The paper does not make clear the rate/frequency of this type of CNV forming mechanism. 48 evolution experiments were performed, but only seven clones were isolated for analysis. It\'s not clear if this report is part of a larger study and this is just a subset of the result. That should be made clearer and if it is part of a larger study the frequency of this mechanism, relative to other mechanisms that generated CNVs at these loci, reported.

3\) The symmetrical stair-step property is really striking, but in some cases this seems imperfect (e.g. 2-4-6-5-3-2). How can the authors rule out that this isn\'t due to noise in the read depth analysis and this should actually be 2-4-6-4-2 or 2-3-5-3-2? i.e. what is the error on the copy number estimation? Is the proposed model expected to generate perfect symmetry?

4\) It is surprising that the evolved strains do not have a growth rate defect in rich media. Does this suggest that there is not selection for the loss of the CNV, but simply that it occurs at a very high rate?

5\) I do not understand the long read sequencing or its interpretation as it is poorly described. How many isolates were analyzed (the Materials and methods section indicates just one)? How can multiple structural variants be detected at a single locus (e.g. eight detected near repeat 127). I think the authors should improve the description and interpretation of these results.

6\) The structure identified from long read sequencing sounds like that found for ODIRA breakpoints (reads switching from the complement to the reverse complement). In addition the stair-step structure is seen at some of the ODIRA-mediated CNVs in budding yeast. Can the authors exclude this DNA replication based mechanism as a possible mechanism forming these CNVs?

Reviewer \#3:

In this Research Advance article, authors Todd and Selmecki identify and characterize several new types of fluconazole/azole-resistant isolates of *C. albicans* that evolve rapidly during growth in the presence of the drug(s) in vitro. Several of these isolates display a remarkable, novel mechanism of drug resistance and tolerance that involves amplification of the copy number of certain chromosome segments by a proposed breakage-fusion-bridge (BFB) model involving the repeated formation and repair of dicentric chromosome intermediates by non-allelic homologous recombination. This BFB model is consistent with the evidence presented and has been proposed to explain similar CNV amplification events in human cancers. The copy number amplification observed in this study is dependent on the presence of two sets of inverted long repeat sequences, which supports the Todd et al., 2019 publication in which previously unidentified long repeat sequences were shown to coincide frequently with breakpoints for CNV and LOH recombination events. This manuscript offers a robust, in-depth characterization of a new mechanism for rapid, adaptive (and reversible) genomic change that builds upon and expands our knowledge of the mechanisms contributing to drug resistance and genome plasticity in human fungal pathogens.

1\) This study provides direct evidence of in vitro evolution by CNV amplification resulting in azole drug resistance/tolerance in *C. albicans*. One limitation of the study is that there is no evidence presented of *C. albicans* isolates evolving azole resistance via this mechanism in the context of a host infection. The authors could offer comments on how this model could be validated by either direct testing of clinical samples from patients treated with fluconazole or in a host model of infection. Also, in the context of a host infection, would there be any limitations to the formation of dicentric intermediates and breakage-fusion-bridge cycles (or would these events be more likely due to host-mediated DNA damaging agents)? Would cells survive and proliferate sufficiently to generate the copy number amplification necessary for resistance by this mechanism before being targeted for clearance by immune cells, particularly in the presence of fluconazole drug treatment that slows growth of the pathogen?

2\) \"Separation of Chrs 4-7 identified a dramatic increase in Chr4 size in two isolates (AMS4702 and AMS4444) with Chr4L CNVs relative to their progenitors and indicates that these CNVs are intra-chromosomal, rather than extra-chromosomal, amplifications (Figure 1---figure supplement 2).\" In Figure 1---figure supplement 2, there is an absence of a band at Chr4 (denoted by the asterisk) compared to the progenitor for both isolates, but no visible \"larger band\" that would correspond to the noted \"dramatic increase in Chr4 size for these isolates.\" Please explain (e.g. is the size of Chr4 too large to resolve/migrate through the gel?).

3\) It is unclear in the text and figures (such as Figure 6) how the asymmetric stair-step copy numbers arise. A figure depicting symmetric vs. asymmetric stair-step copy number amplification would be helpful.

4\) At least some work from budding and fission yeast should be cited (Symington, Kolodner, Lobachev), where genetic control has been examined in some cases. The model with inverted repeats usually involves some type of fold back invasion of an inverted repeat on the same chromosome, followed by BIR to the end, to generate a dicentric.

An example from Kolodner: Putnam et al., 2014.

Fold-backs have also been examined in fission yeast, and these initiated in the context of replication restart:

Mizuno et al., 2013
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Author response

> Reviewer \#2:
>
> \[...\] This is an interesting study. Understanding mechanisms of antifungal resistance is of clear significance and this paper adds to our understanding of the diversity of mechanisms that can be used to generate CNVs underlying drug resistance in C. albicans. Although I do not think that the finding is sufficiently novel to warrant publication as a primary research paper in eLife, the report extends the initial publication by the authors on repeat sequences that mediate CNV formation in the C. albicans genome and therefore is consistent with the aims of the Research Advance format at eLife.
>
> 1\) It is unclear to me the difference between a major repeat sequence (MJR) and a repeat sequence. The authors state that these breakpoints do not occur near MJR, but do occur \"within 2 kb of a long repeat sequence\". What is the difference?

Thank you for indicating that this needed clarification. The Major Repeat Sequence (MRS) in *Candida albicans* is a well-characterized long track (10-100 kb) of nested DNA repeats, found 8 times throughout the genome on 7 of the 8 chromosomes. Previous work identified that the MRS is involved in karyotype rearrangements (Lephart and Magee, 2006). The repeats identified in Todd et al., 2019 are distinct from the MRS class of repeats, and were associated with CNVs, inversions, and loss of heterozygosity in a diverse collection of isolates. We have changed the following sentences to clarify the difference between the MRS and the long repeat sequences.

"All copy number breakpoints occurred within 2 kb of one of the 1974 long repeat sequences identified previously by Todd et al., 2019 (Supplementary file 2)."

"...and were not associated with any centromere (*CEN*) sequence or the *C. albicans* repetitive element known as the Major Repeat Sequence (MRS, found eight times within the *C. albicans* genome) (Chibana et al., 1994; Chindamporn et al., 1998; Lephart et al., 2006)."

> 2\) The paper does not make clear the rate/frequency of this type of CNV forming mechanism. 48 evolution experiments were performed, but only seven clones were isolated for analysis. It\'s not clear if this report is part of a larger study and this is just a subset of the result. That should be made clearer and if it is part of a larger study the frequency of this mechanism, relative to other mechanisms that generated CNVs at these loci, reported.

Thank you for this suggestion. We are very interested in the rate/frequency of these events, especially given that genetically diverse clinical isolates can amplify recurrent CNVs (Figure 1) and that the breakpoints are hotspots for additional genome rearrangements like loss of heterozygosity and inversions in animal models (Todd et al., 2019). Because this is the first study to identify these complex CNVs in *C. albicans*, a robust, in-depth characterization the CNVs and the mechanisms driving their formation is a necessary first step. The seven isolates described are a part of a larger study into the mechanisms that drive antifungal drug resistance in *C. albicans,* however most of the remaining populations have not been analyzed yet by whole genome sequencing. Of the 48 FLC-evolved populations, only 14 have been sequenced and 7/14 have complex CNVs. We now include this frequency in the Results section (subsection "Extensive copy number amplifications occur during adaptation to antifungal stress").

Future studies using single cell analyses with selectable markers are needed to determine the rate of CNV formation during antifungal drug selection and the frequency of these events relative to other adaptive mechanisms. We address the limitations of this study and the need for future experiments that directly quantify the rate of complex CNVs during antifungal drug selection in a new paragraph in the Discussion section (subsection "Model for Complex CNV formation", second paragraph).

> 3\) The symmetrical stair-step property is really striking, but in some cases this seems imperfect (e.g. 2-4-6-5-3-2). How can the authors rule out that this isn\'t due to noise in the read depth analysis and this should actually be 2-4-6-4-2 or 2-3-5-3-2? i.e. what is the error on the copy number estimation? Is the proposed model expected to generate perfect symmetry?

First, to clarify, we observed both symmetric (e.g. AMS4702) and asymmetric (e.g. AMS4105) stair-step amplifications. All symmetric CNVs were associated with two inverted repeat sequences, while the asymmetric CNVs were associated with three inverted repeat sequences. We propose that the asymmetric stair-step CNVs arise via a similar dicentric mechanism as symmetric CNVs, however instead of the dicentric chromosome breaking centromere-proximal it breaks within the chromosome arm and leads to NAHR between different repeat sequences. We added Figure 6---figure supplement 1 to describe an example of asymmetric stair-step formation.

Second, we agree that whole genome sequencing read depth data inherently includes some noise. To calculate the copy numbers, read depth for every position in the genome was determined using samtools. Average read depth was calculated using a 500 bp sliding window. The copy number was calculated by normalizing the average read depth to the average nuclear genome depth and multiplying by two. The copy number for each stair-step of the complex CNV was calculated by averaging the copy number for all 500 bp windows contained in each stair-step. To determine the error of the copy number of each stair-step, we calculated the standard error of the mean (SEM). The SEMs ranged from 0.005 -- 0.383 (SEM was added to Supplementary file 6). To determine if the SEM was consistent across all stair-steps of the complex CNVs, we determined if there was a correlation between copy number and SEM or stair-step length and SEM. There was a positive correlation between copy number and SEM (p \< 0.002, r~2~ = 0.21) and a negative correlation with stair-step length and SEM (p \< 0.003, r~2~ = 0.19), indicating that short, high copy number stair-steps have a higher SEM than longer, lower copy number stair-steps (see example below). To determine if the calculated error would alter copy number, we determined the copy number of each stair-step +/- the SEM, and then normalized to the base diploid genome and then rounded to the nearest integer for biological relevance. Of the 46 copy number stairsteps (Supplementary file 6), only five stair-steps changed copy number upon the incorporation of the SEM. Three of these stair-steps were located between the same long inverted repeat sequence with a short spacer distance (\~5 kb) on Chr3R. For example, AMS4104 Chr3R copy numbers +/- SEM were rounded to: 2-7-13-7-2 or 2-8-13-7-2. Importantly, the overall structure of the complex CNV was not altered, only the rounding of this single stair-step within the CNV. Therefore, we are confident in the copy numbers presented in the manuscript that form both symmetric and asymmetric CNVs.

> 4\) It is surprising that the evolved strains do not have a growth rate defect in rich media. Does this suggest that there is not selection for the loss of the CNV, but simply that it occurs at a very high rate?

We agree that this is surprising, given the size (length and amplitude) of the complex CNVs. However, in general, whole chromosome aneuploidies and CNVs that comprise an entire arm of a chromosome (isochromosomes) are well-tolerated in *C. albicans* (Selmecki et al., 2006; Todd et al., 2019).

Accordingly, the growth rate data support that most of the isolates with a complex CNV do not have a growth rate defect in rich media. Importantly, these complex CNVs are presumed to be maintained on a monocentric chromosome (Figure 1). We do not know the rate in which these CNVs are lost, but there appears to be very little selection for loss based on growth rate. In contrast, isolates with a complex CNV on a dicentric chromosome (and a partial monosomy) have a strong growth defect (Figure 5). Fast growing clones are rapidly isolated from the dicentric isolate (after one plating on rich media) and these clones have lost the dicentric and the partial monosomic chromosomes (via recombination with the remaining full-length homolog). Interestingly, in the absence of drug selection, these fast growing clones include both euploid (WT) clones and clones containing complex CNVs maintained on a monocentric chromosome (like in Figure 1), which further supports that the cells with complex CNVs can compete with WT genotypes.

> 5\) I do not understand the long read sequencing or its interpretation as it is poorly described. How many isolates were analyzed (the Materials and methods section indicates just one)? How can multiple structural variants be detected at a single locus (e.g. eight detected near repeat 127). I think the authors should improve the description and interpretation of these results.

Thank you for these suggestions, as mentioned above in response to reviewer 1: We have made significant changes to Figure 4 and the Figure 4 legend to clarify how the long-read sequencing was used to characterize novel recombination products (fold-back inversions and non-allelic homologous recombination between inverted repeats) in the azole evolved isolate, AMS3051. The only isolate sequenced using the Oxford Nanopore MinION was AMS3051 that contains the Chr3L complex CNV on a dicentric chromosome. We changed the color scheme and added a schematic to show the WT and post-recombination chromosomes. We also modified the Results section to better describe how the long-read sequences supported each of the two structural variants, one at Repeat 124 and one at Repeat 127 (subsection "Recombination occurs between long inverted repeats leading to CNV formation").

> 6\) The structure identified from long read sequencing sounds like that found for ODIRA breakpoints (reads switching from the complement to the reverse complement). In addition the stair-step structure is seen at some of the ODIRA-mediated CNVs in budding yeast. Can the authors exclude this DNA replication based mechanism as a possible mechanism forming these CNVs?

We agree that these two features (complement/reverse complement switching and stair-step patterns) are similar between the copy number breakpoints described in this manuscript and copy number breakpoints attributed to ODIRA. However, to the best of our knowledge, the other key features of ODIRA are not observed in our data. In the ODIRA model of CNV formation, errors during DNA replication result in the ligation of the leading and lagging strands at short (\~8 bp), closely spaced (\~40 bp) inverted repeat sequences within the same replication fork. In contrast, the long inverted repeat sequences associated with the complex CNVs in *C. albicans* are both much longer (median copy length of \~1.7 kb) and separated by a much greater distance (ranging from 1609 bp -- 96,231 bp, median spacer distance \~38,000 bp) than the repeats observed in *S. cerevisiae*. Given the distance between the inverted repeat sequences in *C. albicans*, it is unlikely that the repeats would be present in the same replication fork and undergo ligation of the leading and lagging strands, as in ODIRA. In addition, we determined the distance between the *C. albicans* predicted origins of replication (Tsai et al., 2014) and the long repeat sequences associated with the complex CNVs and found that the nearest predicted origins were located between \~600 bp -- \~100 kb (median distance \~16 kb) away from the long repeats. Therefore, while we cannot formally exclude a DNA replication based mechanism in the formation of *C. albicans* complex CNVs, the length and distance between inverted repeats, and distance between the repeats and origins of replication, makes this unlikely.

> Reviewer \#3:
>
> \[...\] 1) This study provides direct evidence of in vitro evolution by CNV amplification resulting in azole drug resistance/tolerance in C. albicans. One limitation of the study is that there is no evidence presented of C. albicans isolates evolving azole resistance via this mechanism in the context of a host infection. The authors could offer comments on how this model could be validated by either direct testing of clinical samples from patients treated with fluconazole or in a host model of infection. Also, in the context of a host infection, would there be any limitations to the formation of dicentric intermediates and breakage-fusion-bridge cycles (or would these events be more likely due to host-mediated DNA damaging agents)? Would cells survive and proliferate sufficiently to generate the copy number amplification necessary for resistance by this mechanism before being targeted for clearance by immune cells, particularly in the presence of fluconazole drug treatment that slows growth of the pathogen?

Thank you for suggesting additional discussion of our observations in the context of a host infection. We agree that a limitation of this study is that we do not know the rate of dicentric chromosome and complex CNV formation in vitro or in vivo. in vivo passage of *C. albicans* through a mouse model of candidiasis (in the absence of antifungal drug) also identified CNVs at long repeat sequences (Todd et al., 2019). This suggests that these long repeat sequences can generate genomic variation in diverse environments, including in vivo. Host factors, such as reactive oxygen species may increase the rate of DSBs that result in dicentric chromosome formation, in the presence or absence of antifungal drugs. Indeed, dicentric chromosomes have been identified in clinical isolates of *C. albicans*, suggesting that these chromosome structures can form in vivo (Selmecki, 2006). Future studies using single-cell analyses (e.g. Lauer et al., 2018) are needed to determine the rate of complex CNV formation both in vitro and in vivo in the presence and absence of antifungal drugs. We have added a new paragraph to the Discussion section to address these points (subsection "Model for Complex CNV formation", second paragraph).

> 2\) \"Separation of Chrs 4-7 identified a dramatic increase in Chr4 size in two isolates (AMS4702 and AMS4444) with Chr4L CNVs relative to their progenitors and indicates that these CNVs are intra-chromosomal, rather than extra-chromosomal, amplifications (Figure 1---figure supplement 2).\" In Figure 1---figure supplement 2, there is an absence of a band at Chr4 (denoted by the asterisk) compared to the progenitor for both isolates, but no visible \"larger band\" that would correspond to the noted \"dramatic increase in Chr4 size for these isolates.\" Please explain (e.g. is the size of Chr4 too large to resolve/migrate through the gel?).

Thank you for suggesting additional details for this figure. The wild-type Chr4 in *C. albicans* is \~1.6 MB in length. Given the size of complex CNVs in AMS4702 and AMS4444, the estimated size of Chr4 increases to \~3.4 MB and \~2.8 MB. These larger bands co-migrate with Chr1 and ChrR. To address this, we added the chromosome sizes to the CHEF gel image in Figure 1---figure supplement 2, and updated the figure legend.

> 3\) It is unclear in the text and figures (such as Figure 6) how the asymmetric stair-step copy numbers arise. A figure depicting symmetric vs. asymmetric stair-step copy number amplification would be helpful.

Thank you for this suggestion. Asymmetric stair-steps were associated with three inverted repeat sequences, whereas symmetric stair-steps were associated with only two inverted repeat sequences. We propose that the asymmetric stair-step CNVs arise via a similar dicentric mechanism as symmetric CNVs, however instead of the dicentric chromosome breaking centromere-proximal it breaks within the chromosome arm and leads to NAHR between different repeat sequences. We have added Figure 6---figure supplement 1 as an example of asymmetric stair-step formation.

> 4\) At least some work from budding and fission yeast should be cited (Symington, Kolodner, Lobachev), where genetic control has been examined in some cases. The model with inverted repeats usually involves some type of fold back invasion of an inverted repeat on the same chromosome, followed by BIR to the end, to generate a dicentric.
>
> An example from Kolodner: Putnam et al., 2014.
>
> Fold-backs have also been examined in fission yeast, and these initiated in the context of replication restart: Mizuno et al., 2013.

Thank you for these suggestions, we agree that fold back invasion of a repeat sequence on the same chromosome followed by BIR is as likely as NAHR between repeat sequences on sister chromatids. Because we cannot distinguish between these two events, we now indicate that both are possible in the Discussion (subsection "Model for Complex CNV formation", first paragraph) and in the Figure 6 legend, and include the above references accordingly. One interesting distinction is that the long inverted repeats described in this study are separated by greater distances (median spacer distance \~38 kb) than repeat sequences typically involved in fold back invasion and BIR in *S. cerevisiae* and *S. pombe*.
